Oral treatment of rats with bovine lactoferrin inhibits carrageenan-induced inflammation; Correlation with decreased cytokine production

Archivum Immunologiae et Therapiae Experimentalis

Volumn 46, Issue 6, 1998, Pages 361-365

  Zimecki, Michał ^a   Miȩdzybrodzki, Ryszard ^a   Szymaniec, Stanisław ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Bovine lactoferrin; Carrageenan inflammation; Interleukin 6; Rats; Tumor necrosis factor

Indexed keywords

CARRAGEENAN; INTERLEUKIN 6; LACTOFERRIN;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOASSAY; CYTOKINE PRODUCTION; FEMALE; IMMUNOREGULATION; INFLAMMATION; MALE; NONHUMAN; RAT; SPLEEN CELL;

ADMINISTRATION, ORAL; ANIMALS; CARRAGEENAN; CATTLE; CYTOKINES; FEMALE; INFLAMMATION; LACTOFERRIN; MALE; RATS; RATS, WISTAR;

EID: 0032433779     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. ADAMIK B., ZIMECKI M., WŁASZCZYK A., BEREZOWICZ P. S. and KÜBLER A. (1998): Lactoferrin effects on the in vitro immune response in critically ill. Arch. Immunol. Ther. Exp., 46, 169-176.
2. BAUMAN H. and GAULDIE J. (1994): The acute phase response. Immunol. Today, 15, 74-80.
3. BEUTLER B. (1995): TNF, immunity and inflammatory disease: lessons of the past decade. J. Invest. Med., 43, 227-235.
4. BIANCHI M., ROSSONI G., SACERDOTE P., PANERAI A. E. and BERTI F. (1995): Effects of chlomipramine and fluoxetine on subcutaneous carrageenan-induced inflammation in the rat. Inflamm. Res., 44 (11), 466-469.
5. BRITIGAN B. E., HASSET D. J., ROSEN G. M., HAMILL D. R. and COHEN M. S. (1989): Neutrophil degranulation inhibits potential hydroxyl-radical formation. Relative impact of myeloper-oxidase and lactoferrin release on hydroxyl-radical production by iron-supplemented neutrophils assessed by spin-trapping techniques. Biochem. J., 264, 447-455.
6. DEBBABI H., DUBARRY M., RANTUREAU M. and TOME D. (1998): Bovine lactoferrin induces both mucosal and systemic immune response in mice. J. Dairy Res. (in press).
7. ESPEVIK T. and NISSEN-MEYER J. (1986): A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods, 95, 99-105.
8. GRANOWITZ E. V., PORAT R., MIER J. W., ORENCOLE S. F., KAPLANSKI G., LYNCH E. A., YE K., VANNIER E., WOLFF S. M. and DINARELLI C. A. (1993): Intravenous endotoxin suppresses the cytokine responce of peripheral blood mononuclear cells of healthy humans. J. Immunol., 151, 1637-1645.
9. HANSEN M. B., NIELSEN S. E. and BERG K. (1989): Reexamination and further development of a precise and rapid dye method for measuring cell growth/kill. J. Immunol. Methods, 119, 203-210.
10. HONORE P., BURITOVA J. and BESSON J. M. (1995): Aspirin and acetominophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Pain, 63 (3), 365-375.
11. HU W. L., MAZURIER J., MONTREUIL J. and SPIK G. (1990): Izolation and partial characterization of a lactoferrin receptor from mouse intestinal brush border. Biochemistry, 29, 535-541.
12. INGLOT A. D., JANUSZ M. and LISOWSKI J. (1996): Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes. Arch. Immunol. Ther. Exp., 44, 215-224.
13. KARALIS K., MASTORAKOS G., CHROUSOS G. P. and TOLIS G. (1994): Somatostatin analogues suppress the inflammatory reaction in vivo. J. Clin. Invest., 93 (5), 2000-2006.
14. LANTZ M., BJORNBERG F., OLSSON I. and RICHTER J. (1994): Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J. Immunol., 152 (3), 1362-1369.
15. LÖNNERDAL B. and IYER S. (1995): Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr., 15, 93-110.
16. MACHNICKI M., ZIMECKI M. and ZAGULSKI T. (1993): Lactoferrin regulates the release of tumor necrosis factor alpha and interleukin 6 in vivo. Int. J. Exp. Pathol., 74 (5), 433-439.
17. MELARANGE R., BLOWER P. and SPANGLER R. (1994): Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration. Eur. J. Rheumatol. Inflamm., 14 (2), 23-27.
18. MENGOZZI M. and GHEZZI P. (1993): Cytokine down-regulation in endotoxin tolerance. Eur. Cytokine Netw., 4, 89-98.
19. MISIEWICZ B., GRIEBLER C., GOMEZ M., RAYBOURNE R., ZELAZOWSKA E., GOLD P. W. and STERNBERG E. M. (1996): The estrogen antagonist tamoxifen inhibits carrageenan induced inflammation in LEW/N female rats. Life Sci., 58 (16), 281-286.
20. MUKHERJEE A., HALE V. G., BORGA O. and STEIN R. (1996): Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats. Inflamm. Res., 45 (11), 531-540.
21. MUNOZ C., CARLET J., FITTING C., MISSET B., BLERIOT J. P. and CAVAILLON J. M. (1991): Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest., 88, 1747-1754.
22. NAKAGAWA H. and KOMORITA N. (1993): Complement component C3-derived neutrophil chemotactic factors purified from exudate of rat carrageenin-induced inflammation. Biochem. Biophys. Res. Commun., 194 (3), 1181-1187.
23. PARKER R. I., MCKEAN L. P., GALLIN J. I. and GRALNICK H. R. (1992): Absence of the largest platelet-von Willebrand multimers in patient with lactoferrin deficiency and a bleeding tendency. Tromb. Haemost., 67, 320-324.
24. TRUMPLER U. P. W., STRAUB A. and ROSENMUND A. (1989): Antibacterial prophylaxis with lactoferrin in neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis., 8, 310-318.
25. UTSUNOMIYA I., NAGAI S. and OH-ISHI S. (1991): Sequential appearance of IL-I and IL-6 activities in rat carrageenin-induced pleurisy. J. Immunol., 147 (6), 1803-1809.
26. VAN BERKEL P. H., GEERTS M. E., VAN VEEN H. A., KOOIMAN P. M., PIEPER F. R., DE BEER H. A. and NUIJENS J. H. (1995): Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibilities towards tryptic proteolysis. Biochem. J., 312, 107-114.
27. 2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor acivity for B-cells hybridomas. Proc. Natl. Acad. Sci. USA, 83, 9679-9683.
28. VINEGAR R., TRUAX J. F., SELPH J. L., JOHNSTON P. R., VENABLE A. L. and MCKENZIE K. K. (1987): Pathway to carrageenan-induced inflammation in the hind limb of the rat. Federation Proc., 46, 118-126.
29. WŁASZCZYK A., ZIMECKI M., ADAMIK B., DUREK G. and KUBLER A. (1997): Immunological status of patients subjected to cardiac surgery. Effect of lactoferrin on proliferation and production of interleukin 6 and tumor necrosis factor α by peripheral blood mononuclear cells in vitro. Arch. Immunol. Ther. Exp., 45, 201-212.
30. ZAGULSKI T., LIPIŃSKI P., ZAGULSKA A., BRONIEK S. and JARZA̧BEK Z. (1989): Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br. J. Exp. Pathol., 70, 697-704.
31. ZIMECKI M. and MACHNICKI M. (1994): Lactoferrin inhibits the effector phase of the delayed type hypersensivity to sheep erytrocytes and the inflammatory reactions induced by BCG. Arch. Immunol. Ther. Exp., 42, 171-177.
32. - murine thymocytes. Immunol. Lett., 30 (1), 119-123.
33. ZIMECKI M., MAZURIER J., SPIK G. and KAPP J. A. (1995): Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology, 86 (1), 122-127.
34. ZIMECKI M., MAZURIER J., SPIK G. and KAPP J. A. (1996): Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch. Immunol. Ther. Exp., 44 (1), 51-56.
35. ZIMECKI M., WŁASZCZYK A., ZAGULSKI T. and KÜBLER A. (1998): Lactofferin lowers interleukin 6 and tumor necrosis factor α levels in mice subjected to surgery. Arch. Immunol. Ther. Exp., 46, 97-104.
36. ZUCALI J. R., BROXMEYER H. E., LEVY D. and MORSE C. (1989): Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin 1. Blood, 74, 1531-1536.